The latest biotech news

News and Trends 12 Sep 2015

London’s Stock Market is on Fire: Two New Biotech Companies are Going Public

After the invasion of the London stock exchange by US-based companies PureTech (€147M raised) and Verseon (€92M raised) last June, it’s now the turn of two EU companies to go public in the British capital. Shield Therapeutics wants to grab a massive £110 million, while Faron Pharmaceuticals had not disclose its intention yet. Faron, based in Turku (Finland), […]

September 12, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 12 Sep 2015

Top 5 things from outside the EU you need to know this week (Theranos, Google…again, Biogen)

Oh hey there…another Top 5 topics you need to know from outside Europe this week. Hope you enjoy and if you have time, give us some feedback! FOUNDER OF THERANOS: MODERN DIAGNOSIS OF DISEASE IS TOO LATE “If you look up the word ‘diagnose’ in the dictionary, it’ll say ‘to determine the presence of disease from […]

September 12, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 11 Sep 2015

Breast-milk therapy for Microbiome disease makes BioGaia smile

BioGaia is a leading microbiome biotech from Stockholm (Sweden) who use the beneficial bacterium Lactobacillus reuteri to produce probiotic consumables. The biotech is currently investing millions in another Stockholm biotech, Infant Bacterial Therapeutics (IBT). IBT is developing a therapy for Necrotising enterocolitis (NEC) derived from L.reuteri, which is found in human breast-milk. BioGaia is a […]

September 11, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 11 Sep 2015

Cambridge Love Triangle: Leading Biotechs Abcam and Horizon finally collaborate together

This is the story of how Abcam and Horizon fell in collaborative-biotech-love and finally came together to partner up on antibody research. Whilst doing his post-doc at University of Cambridge, Jonathan Milner had an idea to improve how antibodies could be produced for researchers around the World. Thus, he founded the company Abcam in 1998. Over […]

September 11, 2015 - 2 minutesmins - By Philip Hemme

News and Trends 11 Sep 2015

Biom’Up funding goes up Up UP! Surgery tech gets new pot of €31.3M VC

Biom’Up is a Lyon (Fr) Med-tech company which produces biopolymer devices to improve surgery. Launch of their new product Hemoblast has triggered a series C investment round from a large syndicate of European venture capitals. Biom’Up was founded in 2005, experiencing exponential growth since with their biopolymer tech development which achieved a €3M turnover in […]

September 11, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 11 Sep 2015

Biofuels from tobacco: US Tyton and French Deinove partner up

The French green Biotech Deinove continues to strengthen its position in the New World after sealing a new agreement with an American company. Deinove and Tyton BioEnergy systems will bring new solutions to the green chemicals market sector. Deinove’s technology platform produces biofuels and bio-based chemicals by using Deinococcus bacteria as host strains. The bioprocess […]

September 11, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 10 Sep 2015

Roche adds AveXis to its SMA portfolio – determined to dominate market

Swiss Roche is looking to dominate market in Spinal Muscular Atrophy (SMA) research, now also investing in AveXis as part of €58M series D investment in their SMA one-time treatment pipeline. Other veteran VC parties include Deerfield Management and Venrock, with new investors also looking to claim a stake in AveXis SMA candidate treatment. SMA […]

September 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Sep 2015

CureVac, the mRNA Therapy Leader, is invading Moderna’s Homeland!

One more hit to Moderna Therapeutics struck by its German competitor CureVac! The Tübingen-based company just announced the opening of its subsidiary in Boston – hometown of Moderna – and a research collaboration with the U.S. non-profit International AIDS Vaccine Initiative (IAVI) to develop a mRNA-based HIV treatment. CureVac, today announced the official launch of its U.S. operations in […]

September 10, 2015 - 3 minutesmins - By Joachim Eeckhout

News and Trends 10 Sep 2015

Genkyotex’ NOX inhibitor candidate Fails to follow through on Phase II

The French biotech Genkyotex has announced Phase II results for GKT137831 in diabetic kidney disease. The NOX1-4 inhibitor failed to reduce albuminuria. Genkyotex focuses on developing inhibitors of nicotinamide adenine dinucleotide phosphate-oxidase (NADPH) enzymes which are expressed by the NOX-gene family (NOX 1-5). NOX enzymes generate reactive oxidative species (ROS) which if overproduced, can cause […]

September 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 10 Sep 2015

Debiopharm teams up with Solid Biosciences to treat DMD

The Debiopharm Group, headquartered in Lausanne (Switzerland) has announced its Alisporovir brand will under-go preclinical trials to treat Duchenne Muscular Dystrophy (DMD) in collaboration with Solid Biosciences, a Cambridge (MA) biotech dedicated to research of DMD. The Debiopharm Group has been around for over 40 years, with 4 international subsidiary companies within the Swiss-based group. […]

September 10, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Sep 2015

Encouraging results from Tedopi Phase II trials in patients with brain metastases

French Immuno-oncology Biotech OSE Pharma has announced its phase II results for Tedopi trials showing outcome for patients with brain metastases. Announced at the World Conference on Lung Cancer in Denver (US), OSE Pharma revealed how Tedopi had shown interesting results in patients diagnosed with brain metastases from advanced non-small cell lung cancer. Advanced non-small […]

September 9, 2015 - 2 minutesmins - By Dani Bancroft

News and Trends 9 Sep 2015

FDA will use a European Bioinformatics tool to keep patients safe

Molecular Health, a bioinformatics company based in Heidelberg, Germany, today announced that it will enter a commercial-licensing agreement with the US Food and Drugs Standard Agency (FDA) to implement their new bioanalytical product SafetyMAP to analyse risk of marketed drugs. Molecular Health (Labiotech Map Profile here), partnered with MD Anderson (TX) early on, doing consultancy […]

September 9, 2015 - 3 minutesmins - By Dani Bancroft

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

News and Trends

London’s Stock Market is on Fire: Two New Biotech Companies are Going Public

Top 5 things from outside the EU you need to know this week (Theranos, Google…again, Biogen)

Breast-milk therapy for Microbiome disease makes BioGaia smile

Cambridge Love Triangle: Leading Biotechs Abcam and Horizon finally collaborate together

Biom’Up funding goes up Up UP! Surgery tech gets new pot of €31.3M VC

Biofuels from tobacco: US Tyton and French Deinove partner up

Roche adds AveXis to its SMA portfolio – determined to dominate market

CureVac, the mRNA Therapy Leader, is invading Moderna’s Homeland!

Genkyotex’ NOX inhibitor candidate Fails to follow through on Phase II

Debiopharm teams up with Solid Biosciences to treat DMD

Encouraging results from Tedopi Phase II trials in patients with brain metastases

FDA will use a European Bioinformatics tool to keep patients safe

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!